David F Fiorentino, MD

Offices

3 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

11 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Fiorentino’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

11 of 11 plans

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
SCAN Strive (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
DualConnect (HMO D-SNP)	Santa Clara Family Health Plan	Listed	Sep 1, 2026

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Stanford Health Care

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	5.31 (4.24 to 6.37) · 8,661 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	14.1 (12.7 to 15.7) · 2,191 cases	Worse	Jan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths	4.08 (1.95 to 6.21) · 5,296 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.317	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.446	Better	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.241	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.7 (0.6 to 0.9) · 3,348 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.06 (0.45 to 1.67) · 5,374 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.86 (0.72 to 1)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	166.09 (137.88 to 194.3) · 470 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.1 · 192 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	6.4 · 146 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	9.7 · 253 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.3 · 880 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 935 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.7 · 501 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.1 · 7,730 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.13 (0 to 0.27) · 20,799 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.28 (0.14 to 0.43) · 23,182 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.94 (0.2 to 1.68) · 5,694 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2.36 (1.54 to 3.19) · 7,846 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5.2 (3.76 to 6.64) · 5,603 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.38 (0.23 to 2.53) · 2,211 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.52 (0.21 to 0.83) · 19,915 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.6 · 416 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.869	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.857	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.368	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16.2 · 247 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20.5 · 1,021 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	47.8 · 258 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-1.6 · 990 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	20.8 · 976 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.5 · 959 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.2 (4.4 to 6.2) · 2,191 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 425 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	9.6 · 158 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	19.6 · 183 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	12.7 (10.4 to 15.4) · 4,578 cases	No different	Jan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at Stanford Health Care

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at Stanford Health Care

Room was "always" clean	75%
Nurses "always" communicated well	82%
Doctors "always" communicated well	81%
Staff "always" explained	63%
Yes, staff "did" give patients this information	89%
Yes, staff "did" give patients information about help after discharge	89%
Doctors "always" explained things so they could understand	76%
Doctors "always" listened carefully	80%
Doctors "always" treated them with courtesy and respect	87%
Patients who gave a rating of "9" or "10" (high)	79%
Staff "always" explained new medications	76%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	79%
Nurses "always" treated them with courtesy and respect	88%
"Always" quiet at night	53%
"YES", patients would definitely recommend the hospital	83%
Staff "always" explained possible side effects	50%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$23,689

Medicare paid this office $23,689 for 98 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Return visit (30+ min)	53	$9,321	$86
Long return visit (40+ min)	36	$8,090	$135
New patient visit (60+ min)	18	$2,750	$153
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	51	$1,347	$15
Short return visit (20+ min)	11	$821	$59

Procedures Medicare counted

Sort by

Procedure volume Medicare published

Removal of skin lesions	1-10	None
Skin biopsy	1-10	None

Who their Medicare patients are

98 Original Medicare patients in 2024. Average age 71 · Women 81% · Also on Medicaid 13% · Health risk score 1.73. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 59% · Depression 24% · Chronic kidney disease 22% · Coronary heart disease 21% · Diabetes 19% · Cancer 17% · COPD 14% · Heart failure 12%.

The office billed $70,096, Medicare allowed $31,259 and paid $23,689; for 327 services of 16 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	98	327	71	1.73	$70,096	$23,689
2023	96	218	71	2.26	$54,807	$17,834
2022	85	202	71	1.64	$46,396	$15,867
2021	92	215	68	1.51	$57,665	$18,451
2020	96	191	68	1.58	$57,880	$12,606
2019	175	685	71	1.74	$70,821	$26,870
2018	182	622	71	1.64	$64,246	$26,601
2017	179	689	71	1.50	$76,870	$26,579
2016	181	548	70	1.46	$69,836	$20,023
2015	205	746	70	1.41	$102,748	$29,848
2014	210	765	69	1.30	$104,876	$30,438
2013	197	696	69	1.19	$93,572	$27,208

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 4 services

Sort by

Original Medicare services billed in 2023

Return visit (30+ min)	51	$7,623	$81
Long return visit (40+ min)	19	$3,421	$127
Short return visit (20+ min)	27	$2,768	$53
New patient visit (60+ min)	15	$2,321	$155

2022: 4 services

Sort by

Original Medicare services billed in 2022

Return visit (30+ min)	55	$6,945	$81
Long return visit (40+ min)	19	$2,833	$123
Short return visit (20+ min)	27	$2,371	$53
New patient visit (45+ min)	15	$1,735	$116

2021: 4 services

Sort by

Original Medicare services billed in 2021

Return visit (30+ min)	63	$7,967	$86
Long return visit (40+ min)	30	$4,898	$126
New patient visit (45+ min)	13	$1,638	$126
Short return visit (20+ min)	16	$1,070	$56

2020: 4 services

Sort by

Original Medicare services billed in 2020

Return visit (30+ min)	44	$4,693	$70
Long return visit (40+ min)	32	$3,837	$87
New patient visit (30+ min)	14	$898	$64
Short return visit (20+ min)	12	$468	$39

2019: 8 services

Sort by

Original Medicare services billed in 2019

Return visit (30+ min)	86	$8,026	$66
Long return visit (40+ min)	42	$4,790	$94
Short return visit (20+ min)	71	$4,283	$40
Destruction of precancer skin growth, 1 growth	44	$2,791	$47
Destruction of skin growth, 1-14 growths	14	$1,611	$60
New patient visit (60+ min)	11	$1,530	$139
Biopsy of related skin growth, first growth	21	$527	$22
Destruction of precancer skin growth, 2-14 growths	34	$478	$2

2018: 9 services

Sort by

Original Medicare services billed in 2018

Return visit (30+ min)	66	$6,519	$67
Short return visit (20+ min)	86	$5,422	$42
Long return visit (40+ min)	41	$4,851	$93
Destruction of precancer skin growth, 1 growth	37	$2,205	$44
New patient visit (60+ min)	15	$2,091	$139
Destruction of skin growth, 1-14 growths	21	$1,658	$64
Biopsy of single growth of skin and/or tissue	35	$1,238	$33
Destruction of precancer skin growth, 2-14 growths	32	$357	$2
Biopsy of each additional growth of skin and/or tissue	11	$293	$23

2017: 9 services

Sort by

Original Medicare services billed in 2017

Return visit (30+ min)	69	$7,017	$67
Short return visit (20+ min)	99	$6,020	$42
Long return visit (40+ min)	33	$3,992	$91
Destruction of precancer skin growth, 1 growth	41	$2,539	$43
New patient visit (45+ min)	17	$1,839	$108
Biopsy of single growth of skin and/or tissue	31	$1,133	$35
Destruction of skin growth, 1-14 growths	17	$1,128	$59
Destruction of precancer skin growth, 2-14 growths	31	$417	$2
Biopsy of each additional growth of skin and/or tissue	11	$317	$21

2016: 8 services

Sort by

Original Medicare services billed in 2016

Short return visit (20+ min)	100	$5,582	$39
Return visit (30+ min)	62	$4,965	$59
Destruction of precancer skin growth, 1 growth	41	$1,964	$39
Long return visit (40+ min)	19	$1,906	$79
New patient visit (45+ min)	13	$1,348	$104
Destruction of skin growth, 1-14 growths	16	$1,095	$64
Biopsy of single growth of skin and/or tissue	25	$893	$33
Destruction of precancer skin growth, 2-14 growths	27	$282	$2

2015: 10 services

Sort by

Original Medicare services billed in 2015

Return visit (30+ min)	77	$8,497	$66
Short return visit (20+ min)	112	$6,702	$40
Long return visit (40+ min)	29	$3,010	$89
Destruction of precancer skin growth, 1 growth	45	$2,461	$40
New patient visit (45+ min)	20	$2,303	$115
Biopsy of single growth of skin and/or tissue	35	$1,392	$36
Destruction of skin growth, 1-14 growths	21	$1,380	$60
New patient visit (30+ min)	13	$606	$47
Destruction of precancer skin growth, 2-14 growths	37	$426	$2
Biopsy of each additional growth of skin and/or tissue	12	$385	$23

2014: 10 services

Sort by

Original Medicare services billed in 2014

Return visit (30+ min)	70	$7,732	$61
Short return visit (20+ min)	104	$6,616	$39
Long return visit (40+ min)	26	$3,605	$92
Destruction of precancer skin growth, 1 growth	41	$2,579	$42
New patient visit (45+ min)	22	$2,519	$114
New patient visit (60+ min)	12	$1,797	$150
Destruction of skin growth, 1-14 growths	19	$1,741	$64
New patient visit (30+ min)	23	$1,461	$64
Biopsy of single growth of skin and/or tissue	40	$1,405	$34
Destruction of precancer skin growth, 2-14 growths	38	$453	$2

2013: 9 services

Sort by

Original Medicare services billed in 2013

Return visit (30+ min)	71	$8,654	$63
Short return visit (20+ min)	95	$5,720	$40
Destruction of precancer skin growth, 1 growth	42	$2,603	$44
New patient visit (45+ min)	20	$1,921	$96
Long return visit (40+ min)	14	$1,864	$81
New patient visit (30+ min)	29	$1,723	$59
Biopsy of single growth of skin and/or tissue	29	$1,004	$31
Destruction of skin growth, 1-14 growths	16	$842	$50
Destruction of precancer skin growth, 2-14 growths	36	$792	$4

Drugs they prescribed that Part D paid

$2,283,168

Pharmacies billed $2,283,168 in 2024. Most of that is three immune-globulin drugs at $13,000–$19,000 a fill for a small number of people.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 406) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.

264 generic and 142 brand-name prescriptions · $2,283,168 in drug cost · 19 antibiotic prescriptions.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Gammaplex	Immune globulin	57	$1,081,025	$18,965
Privigen	Immune globulin	39	$641,966	$16,461
Lenalidomide	None	13	$196,534	$15,118
Gammaked	Immune globulin	13	$172,564	$13,274
Mycophenolate Mofetil	None	34	$3,165	$93

See all 9 drugs

Sort by

Every Part D drug this clinician prescribed

Gammaplex	Immune globulin	57	$1,081,025	$18,965
Privigen	Immune globulin	39	$641,966	$16,461
Lenalidomide	None	13	$196,534	$15,118
Gammaked	Immune globulin	13	$172,564	$13,274
Mycophenolate Mofetil	None	34	$3,165	$93
Colchicine	None	14	$2,033	$145
Clobetasol Propionate	None	16	$709	$44
Prednisone	None	48	$436	$9
Methotrexate	None	25	$324	$13

Year by year

Sort by

Part D prescribing by year

2024	406	54	0% (0)	35%	$2,283,168
2023	353	42	None	45%	$2,159,611
2022	318	46	None	31%	$1,470,014
2021	344	51	0% (0)	None	$1,131,695
2020	328	62	0% (0)	None	$865,687
2019	544	104	0% (0)	27%	$918,819
2018	695	120	0% (0)	18%	$584,725
2017	650	111	None	19%	$472,289
2016	623	98	0% (0)	19%	$435,944
2015	871	126	None	20%	$530,984
2014	875	120	None	19%	$482,255
2013	776	121	None	22%	$519,819

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 8 drugs

Sort by

Part D drugs prescribed in 2023

Gammaplex	Immune globulin	53	$1,020,977	$19,264
Privigen	Immune globulin	19	$363,083	$19,110
Gammaked	Immune globulin	24	$283,096	$11,796
Gamunex-C	Immune globulin	30	$236,751	$7,892
Clobetasol Propionate	None	11	$1,479	$134
Triamcinolone Acetonide	None	13	$520	$40
Methotrexate	None	21	$348	$17
Prednisone	None	49	$273	$6

2022: 10 drugs

Sort by

Part D drugs prescribed in 2022

Gamunex-C	Immune globulin	24	$479,432	$19,976
Gammaplex	Immune globulin	20	$452,822	$22,641
Gammaked	Immune globulin	18	$261,943	$14,552
Benlysta	None	12	$54,214	$4,518
Mycophenolate Mofetil	None	17	$2,849	$168
Hydroxychloroquine Sulfate	None	16	$1,503	$94
Clobetasol Propionate	None	13	$724	$56
Methotrexate	None	21	$694	$33
Prednisone	None	57	$529	$9
Gabapentin	None	16	$270	$17

2021: 8 drugs

Sort by

Part D drugs prescribed in 2021

Gamunex-C	Immune globulin	18	$346,948	$19,275
Gammagard Liquid	Immune globulin	30	$334,561	$11,152
Gammaplex	Immune globulin	17	$292,349	$17,197
Hydroxychloroquine Sulfate	None	33	$2,212	$67
Mycophenolate Mofetil	None	23	$2,027	$88
Methotrexate	None	24	$915	$38
Prednisone	None	60	$640	$11
Gabapentin	None	14	$175	$13

2020: 10 drugs

Sort by

Part D drugs prescribed in 2020

Gamunex-C	Immune globulin	14	$221,188	$15,799
Calcipotriene	None	17	$3,143	$185
Hydroxychloroquine Sulfate	None	30	$2,326	$78
Chloroquine Phosphate	None	11	$1,874	$170
Sildenafil Citrate	None	17	$1,337	$79
Mycophenolate Mofetil	None	18	$1,263	$70
Clobetasol Propionate	None	12	$1,101	$92
Triamcinolone Acetonide	None	17	$664	$39
Methotrexate	None	11	$341	$31
Prednisone	None	37	$272	$7

2019: 16 drugs

Sort by

Part D drugs prescribed in 2019

Cosentyx Pen (2 Pens)	23	$170,909	$7,431
Humira	22	$118,110	$5,369
Sildenafil Citrate	27	$4,176	$155
Mycophenolate Mofetil	34	$4,071	$120
Calcipotriene	21	$3,890	$185
Tacrolimus	11	$3,437	$312
Desonide	14	$2,327	$166
Clobetasol Propionate	17	$2,220	$131
Fluocinonide	22	$1,478	$67
Methotrexate	21	$1,164	$55
Hydroxychloroquine Sulfate	17	$1,089	$64
Triamcinolone Acetonide	28	$598	$21
Prednisone	43	$566	$13
Ketoconazole	13	$241	$19
Gabapentin	13	$142	$11
Hydrocortisone	13	$78	$6

2018: 18 drugs

Sort by

Part D drugs prescribed in 2018

Humira	29	$152,760	$5,268
Cosentyx Pen (2 Pens)	28	$134,313	$4,797
Sildenafil	25	$12,078	$483
Calcipotriene	17	$7,350	$432
Mycophenolate Mofetil	79	$7,309	$93
Clobetasol Propionate	29	$3,208	$111
Desonide	18	$3,121	$173
Hydroxychloroquine Sulfate	30	$2,135	$71
Methotrexate	31	$1,888	$61
Dapsone	11	$1,349	$123
Fluocinonide	20	$1,172	$59
Betamethasone Dipropionate	16	$1,117	$70
Prednisone	69	$751	$11
Triamcinolone Acetonide	42	$669	$16
Finasteride	14	$314	$22
Ketoconazole	12	$191	$16
Hydroxyzine	16	$143	$9
Gabapentin	12	$123	$10

2017: 15 drugs

Sort by

Part D drugs prescribed in 2017

Humira	27	$125,094	$4,633
Cosentyx Pen (2 Pens)	26	$116,206	$4,469
Acitretin	11	$12,196	$1,109
Mycophenolic Acid	12	$11,936	$995
Sildenafil	29	$7,675	$265
Calcipotriene	15	$6,934	$462
Clobetasol Propionate	40	$6,269	$157
Mycophenolate Mofetil	49	$5,015	$102
Fluocinonide	23	$2,916	$127
Hydroxychloroquine Sulfate	25	$2,729	$109
Methotrexate	38	$1,824	$48
Doxepin	11	$1,116	$101
Prednisone	89	$896	$10
Triamcinolone Acetonide	57	$713	$13
Hydroxyzine	14	$193	$14

2016: 19 drugs

Sort by

Part D drugs prescribed in 2016

Humira	23	$106,649	$4,637
Cosentyx Pen (2 Pens)	14	$98,258	$7,018
Fluocinonide	37	$6,957	$188
Calcipotriene	13	$6,118	$471
Mycophenolate Mofetil	50	$4,972	$99
Clobetasol Propionate	30	$4,619	$154
Desonide	16	$2,695	$168
Hydroxychloroquine Sulfate	27	$2,639	$98
Dapsone	11	$1,722	$157
Azathioprine	15	$1,416	$94
Methotrexate	18	$1,012	$56
Sildenafil	19	$1,006	$53
Prednisone	75	$1,001	$13
Triamcinolone Acetonide	33	$704	$21
Ketoconazole	18	$404	$22
Omeprazole	20	$246	$12
Hydroxyzine	11	$215	$20
Hydrocortisone	13	$111	$9
Amlodipine Besylate	11	$16	$1

2015: 25 drugs

Sort by

Part D drugs prescribed in 2015

Stelara	12	$154,157	$12,846
Humira	28	$109,837	$3,923
Humira	17	$67,015	$3,942
Sildenafil	22	$15,664	$712
Acitretin	11	$15,433	$1,403
Clobetasol Propionate	46	$8,517	$185
Calcipotriene	17	$7,266	$427
Mycophenolate Mofetil	54	$6,814	$126
Fluocinonide	38	$4,819	$127
Hydroxychloroquine Sulfate	39	$4,769	$122
Desonide	25	$4,167	$167
Methotrexate	50	$3,281	$66
Azathioprine	20	$2,566	$128
Betamethasone Dipropionate	11	$2,330	$212
Prednisone	111	$1,939	$17
Triamcinolone Acetonide	45	$1,099	$24
Chloroquine Phosphate	17	$701	$41
Leflunomide	12	$563	$47
Hydroxyzine	17	$421	$25
Doxepin	15	$320	$21
Omeprazole	14	$261	$19
Mupirocin	14	$165	$12
Cephalexin	13	$149	$11
Pantoprazole	12	$113	$9
Alendronate	13	$103	$8

2014: 21 drugs

Sort by

Part D drugs prescribed in 2014

Humira	52	$159,665	$3,070
Sildenafil	22	$24,738	$1,124
Calcipotriene	20	$12,657	$633
Mycophenolate Mofetil	51	$10,308	$202
Desonide	41	$9,443	$230
Clobetasol Propionate	51	$3,894	$76
Fluocinonide	39	$3,501	$90
Methotrexate	35	$2,946	$84
Prednisone	92	$1,191	$13
Azathioprine	11	$1,183	$108
Triamcinolone Acetonide	50	$935	$19
Chloroquine Phosphate	23	$869	$38
Doxepin	18	$755	$42
Hydroxychloroquine Sulfate	23	$703	$31
Hydroxyzine	17	$345	$20
Omeprazole	24	$249	$10
Gabapentin	12	$239	$20
Alendronate	23	$231	$10
Escitalopram	11	$227	$21
Pantoprazole	15	$111	$7
Amlodipine Besylate	16	$72	$4

2013: 19 drugs

Sort by

Part D drugs prescribed in 2013

Stelara	18	$182,779	$10,154
Humira	44	$116,826	$2,655
Sildenafil	21	$40,761	$1,941
Calcipotriene	23	$14,362	$624
Mycophenolate Mofetil	51	$10,626	$208
Desonide	23	$4,985	$217
Fluocinonide	43	$2,542	$59
Clobetasol Propionate	43	$1,182	$27
Mometasone Furoate	16	$1,003	$63
Hydroxyzine	26	$748	$29
Doxepin	15	$696	$46
Prednisone	83	$692	$8
Dapsone	12	$658	$55
Triamcinolone Acetonide	34	$568	$17
Omeprazole	17	$525	$31
Cilostazol	11	$427	$39
Nifedical Xl	12	$392	$33
Pentoxifylline	11	$317	$29
Cephalexin	12	$273	$23

Money from drug and device companies

$13,984 in 2025

Sort by

Industry payments by year

2025	6	10	$13,872	$13,984
2024	5	11	$15,379	$15,979
2023	5	14	$17,062	$17,141
2022	5	15	$22,658	$24,293
2021	6	15	$21,698	$23,198
2020	4	15	$18,075	$19,610
2019	6	26	$49,415	$52,119

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Pfizer	None	$3,799	3 payments Consulting · 2025-05-16 · $544 Consulting · 2025-03-03 · $1,088 Consulting · 2025-01-13 · $2,168
Legend Biotech USA	None	$2,925	1 payment Consulting · 2025-11-19 · $2,925
Ucb Sa	Cimzia	$2,560	2 payments Consulting · 2025-11-28 · $900 Consulting for Cimzia · 2025-08-01 · $1,660
Janssen Scientific Affairs	Tremfya	$2,250	1 payment Consulting for Tremfya · 2025-10-02 · $2,250
Argenx US	None	$1,550	2 payments Meals · 2025-10-26 · $112 Consulting · 2025-10-01 · $1,438
Boehringer Ingelheim Pharmaceuticals	None	$900	1 payment Consulting · 2025-12-17 · $900

See all 10 published payments

Sort by

Every published payment

Boehringer Ingelheim Pharmaceuticals	Consulting · 2025-12-17	None	$900
Ucb Sa	Consulting · 2025-11-28	None	$900
Legend Biotech USA	Consulting · 2025-11-19	None	$2,925
Argenx US	Meals · 2025-10-26	None	$112
Janssen Scientific Affairs	Consulting · 2025-10-02	Tremfya	$2,250
Argenx US	Consulting · 2025-10-01	None	$1,438
Ucb Sa	Consulting · 2025-08-01	Cimzia	$1,660
Pfizer	Consulting · 2025-05-16	None	$544
Pfizer	Consulting · 2025-03-03	None	$1,088
Pfizer	Consulting · 2025-01-13	None	$2,168

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $15,979

Sort by

Payments by company in 2024

Argenx US	None	$5,528	3 payments Consulting · 2024-12-18 · $750 Consulting · 2024-12-04 · $2,153 Consulting · 2024-01-03 · $2,625
Pfizer	None	$5,261	2 payments Consulting · 2024-11-27 · $1,938 Consulting · 2024-03-18 · $3,323
Ucb Sa	Cimzia	$2,490	1 payment Consulting for Cimzia · 2024-06-21 · $2,490
E.R. Squibb & Sons L.L.C.	None	$1,500	1 payment Consulting · 2024-01-05 · $1,500
Janssen Scientific Affairs	Remicade	$1,200	4 payments Consulting for Remicade · 2024-05-24 · $300 Consulting for Remicade · 2024-05-24 · $300 Meals for Remicade · 2024-05-24 · $300 Travel for Remicade · 2024-05-24 · $300

2023: $17,141

Sort by

Payments by company in 2023

Ucb Sa	Cimzia	$6,225	3 payments Consulting for Cimzia · 2023-07-20 · $1,660 Consulting · 2023-06-23 · $830 Consulting · 2023-01-20 · $3,735
Pfizer	Xeljanz	$4,791	7 payments Consulting · 2023-11-24 · $2,417 Consulting · 2023-10-10 · $483 Meals for Xeljanz · 2023-09-08 · $33 Consulting · 2023-05-29 · $1,813 Meals · 2023-05-11 · $15 Education for Cibinqo · 2023-05-10 · $15 Education for Cibinqo · 2023-04-12 · $15
E.R. Squibb & Sons L.L.C.	None	$3,000	1 payment Consulting · 2023-08-07 · $3,000
Argenx US	None	$1,875	2 payments Consulting · 2023-10-25 · $1,125 Consulting · 2023-07-06 · $750
EMD Serono Research & Development Institute	None	$1,250	1 payment Consulting · 2023-07-26 · $1,250

2022: $24,293

Sort by

Payments by company in 2022

Ucb Sa	Cimzia	$16,808	6 payments Consulting · 2022-11-04 · $830 Consulting · 2022-10-28 · $3,320 Consulting for Cimzia · 2022-07-15 · $2,283 Consulting · 2022-07-15 · $4,565 Consulting for Cimzia · 2022-04-15 · $830 Consulting · 2022-04-15 · $4,980
E.R. Squibb & Sons L.L.C.	None	$3,750	3 payments Consulting · 2022-12-12 · $1,500 Consulting · 2022-09-28 · $750 Consulting · 2022-06-10 · $1,500
Janssen Scientific Affairs	Remicade	$3,000	4 payments Meals for Remicade · 2022-03-09 · $750 Consulting for Remicade · 2022-03-09 · $750 Travel for Remicade · 2022-03-09 · $750 Consulting for Remicade · 2022-03-09 · $750
BeiGene	Brukinsa	$600	1 payment Consulting for Brukinsa · 2022-05-18 · $600
Ucb	None	$135	1 payment Meals · 2022-07-16 · $135

2021: $23,198

Sort by

Payments by company in 2021

Ucb Sa	Cimzia	$7,623	4 payments Consulting for Cimzia · 2021-11-26 · $623 Consulting · 2021-07-23 · $2,240 Consulting · 2021-04-30 · $2,800 Consulting · 2021-02-04 · $1,960
Amgen	None	$6,050	3 payments Consulting · 2021-09-27 · $3,300 Consulting · 2021-07-02 · $1,650 Consulting · 2021-03-25 · $1,100
E.R. Squibb & Sons L.L.C.	None	$3,000	2 payments Consulting · 2021-10-19 · $1,500 Consulting · 2021-06-23 · $1,500
Janssen Scientific Affairs	Remicade	$3,000	4 payments Consulting for Remicade · 2021-12-30 · $750 Travel for Remicade · 2021-12-30 · $750 Meals for Remicade · 2021-12-30 · $750 Consulting for Remicade · 2021-12-30 · $750
Pfizer	None	$2,925	1 payment Consulting · 2021-08-27 · $2,925
BeiGene	None	$600	1 payment Consulting · 2021-06-24 · $600

2020: $19,610

Sort by

Payments by company in 2020

Ucb Sa	Cimzia	$10,175	4 payments Consulting · 2020-12-10 · $1,960 Consulting · 2020-08-06 · $1,680 Consulting · 2020-04-30 · $5,320 Consulting for Cimzia · 2020-04-24 · $1,215
Janssen Scientific Affairs	Remicade	$4,800	8 payments Consulting for Remicade · 2020-07-07 · $750 Meals for Remicade · 2020-07-07 · $750 Travel for Remicade · 2020-07-07 · $750 Consulting for Remicade · 2020-07-07 · $750 Consulting for Remicade · 2020-02-03 · $450 Consulting for Remicade · 2020-02-03 · $450 Consulting for Remicade · 2020-02-03 · $450 Consulting for Remicade · 2020-02-03 · $450
E.R. Squibb & Sons L.L.C.	None	$2,400	1 payment Consulting · 2020-12-02 · $2,400
Amgen	None	$2,235	2 payments Consulting · 2020-12-23 · $2,200 Meals · 2020-02-13 · $35

2019: $52,119

Sort by

Payments by company in 2019

Pfizer	None	$22,652	2 payments Meals · 2019-03-05 · $152 Consulting · 2019-01-28 · $22,500
UCB Biosciences	None	$19,740	2 payments Consulting · 2019-11-04 · $2,240 Consulting · 2019-07-05 · $17,500
Janssen Scientific Affairs	Remicade	$8,993	16 payments Consulting for Remicade · 2019-06-21 · $1,500 Consulting for Remicade · 2019-06-21 · $1,500 Consulting for Remicade · 2019-06-21 · $1,500 Consulting for Remicade · 2019-06-21 · $1,500 Travel for Stelara · 2019-05-16 · $1,352 Meals for Stelara · 2019-05-16 · $15 Meals for Stelara · 2019-05-16 · $50 Meals for Stelara · 2019-05-16 · $15 Meals for Stelara · 2019-05-16 · $150 Meals for Stelara · 2019-05-16 · $30 Meals for Stelara · 2019-05-16 · $22 Travel for Stelara · 2019-05-16 · $159 Consulting for Remicade · 2019-01-04 · $300 Meals for Remicade · 2019-01-04 · $300 Consulting for Remicade · 2019-01-04 · $300 Travel for Remicade · 2019-01-04 · $300
AbbVie	None	$575	1 payment Consulting · 2019-12-19 · $575
Amgen	Enbrel	$144	4 payments Meals · 2019-12-13 · $45 Meals · 2019-11-04 · $86 Meals · 2019-10-17 · $3 Meals for Enbrel · 2019-07-26 · $9
AbbVie	Skyrizi	$15	1 payment Education for Skyrizi · 2019-07-25 · $15

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

PFIZER INC. · A Phase 2a Doubleblind Randomized Placebocontrolled Study To Evaluate the Efficacy Safety and Tolerability of Pf06823859 in Adult Subjects With Dermatomyositis · 2020	Their institution	$53,195
PFIZER INC. · A Transcriptomic Analysis of Dermatomyositis · 2020	Their institution	$50,000
PFIZER INC. · A Phase 2a Doubleblind Randomized Placebocontrolled Study To Evaluate the Efficacy Safety and Tolerability of Pf06823859 in Adult Subjects With Dermatomyositis · 2019	Their institution	$48,563
PFIZER INC. · A Phase 2a Doubleblind Randomized Placebocontrolled Study To Evaluate the Efficacy Safety and Tolerability of Pf06823859 in Adult Subjects With Dermatomyositis · 2022	Their institution	$45,905
PFIZER INC. · A Phase 2a Doubleblind Randomized Placebocontrolled Study To Evaluate the Efficacy Safety and Tolerability of Pf06823859 in Adult Subjects With Dermatomyositis · 2023	Their institution	$34,099
ARGENX US, INC. · A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study To Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Efgartigimod Ph20 Sc in Participants Aged 18 Years and Older With Acve Idiopathic Inflammatory Myopathy · 2023	Their institution	$23,652
ARGENX US, INC. · A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study To Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod Ph20 Sc in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy · 2025	Their institution	$23,206
PFIZER INC. · A Phase 2a Doubleblind Randomized Placebocontrolled Study To Evaluate the Efficacy Safety and Tolerability of Pf06823859 in Adult Subjects With Dermatomyositis · 2021	Their institution	$13,912
PFIZER INC. · A Phase 2a Doubleblind Randomized Placebocontrolled Study To Evaluate the Efficacy Safety and Tolerability of Pf06823859 in Adult Subjects With Dermatomyositis · 2022	This clinician	$9,602
ARGENX US, INC. · A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study To Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod Ph20 Sc in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy · 2024	Their institution	$7,688
Octapharma USA, Inc. · Octagam Immune Globulin (Human) · 2019	This clinician	$6,000
PFIZER INC. · Pf07038124 Brepocitinib Dazukibart Pf06763809 Dekavil Pf06817024 Pf06480605 Ritlecitinib Zimlovisertib Pf06826647 Pf06835375 Multi Product Pf07054894 Pf06473871 Clinical Publication Program · 2024	This clinician	$3,200
Amgen Inc. · Abp 654 P3 Pso Study · 2022	This clinician	$3,163
PFIZER INC. · Zimlovisertib Clinical Publication Program · 2023	This clinician	$1,270
PFIZER INC. · Brepocitinib Clinical Publication Program · 2023	This clinician	$1,270
Amgen Inc. · Interchangeability Study Abp 654 · 2022	This clinician	$688
Octapharma USA, Inc. · Octagam Immune Globulin (Human) · 2020	This clinician	$500
PFIZER INC. · Ritlecitinib Clinical Publication Program · 2022	This clinician	$330

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 76.5 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1740335025
Licence: CA A069579
Trained: Stanford University School of Medicine, 1988
Group: Stanford Health Care
Video visits: Lists video visits
Gender: Male

More record details

Sole proprietor: No
Taxonomy: Federal specialty code 207N00000X (207N00000X)
Mailing address: 532 Paco Dr, Los Altos, CA, 94024
NPI first listed: 2007-01-24
NPI last updated: 2024-04-16
NPI record certified: 2024-04-16

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 900 Blake Wilbur Dr, Palo Alto, CA, 94304 · 440 Broadway St Fl B4, Redwood City, CA, 94063